Intravascular hemolysis after pulsed field ablation for atrial fibrillation: A comparative analysis of 3 systems

房颤脉冲场消融术后血管内溶血:3种系统的比较分析

阅读:2

Abstract

BACKGROUND: Intravascular hemolysis after pulsed field ablation (PFA) for atrial fibrillation contributes to renal dysfunction; however, the extent and clinical relevance may differ depending on the ablation system used. OBJECTIVE: This study aimed to compare the extent of intravascular hemolysis across 3 pulmonary vein isolation (PVI) systems in patients with atrial fibrillation. METHODS: This single-center study included consecutive patients who underwent PVI using 1 of the 3 PFA systems: FARAWAVE (FARA) (n = 29), VARIPULSE (VARI) (n = 30), or PulseSelect (PSelect) (n = 32). Haptoglobin levels and myocardial injury biomarkers were evaluated at 3 time points: before the procedure (T1), immediately after the procedure (T2), and the next day after the procedure (T3). RESULTS: PVI was performed using standard application counts for each system (median [interquartile range] FARA 34 [33-37], VARI 18 [17-20], and PSelect 48 [42-49]; P < .001). Haptoglobin levels (mg/dL) significantly decreased from baseline at T2 and T3 in all groups, with a more pronounced decline observed in the FARA group at T3 than in the PSelect (25 [16-50] vs. 60 [34-86]; P < .01). Lactate dehydrogenase levels increased significantly at T2 in the FARA and VARI groups, but not in the PSelect group. Other myocardial biomarkers (creatine kinase and aspartate aminotransferase) showed comparable increases across systems. No clinically significant renal impairment or acute kidney injury occurred in any of the groups. CONCLUSION: Intravascular hemolysis is frequent yet generally subclinical after PFA. FARA exhibited higher hemolysis than PSelect, whereas VARI demonstrated an intermediate profile. Despite these differences, no clinically meaningful renal impairment was observed under standard application counts.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。